Multiple sclerosis and pregnancy

Baranenko O.M.

Main
Publications
Multiple sclerosis and pregnancy

July 22, 2020

980

Obstetrics and Gynecology

Neurology and Psychiatry

Baranenko O.M.

Keywords :

multiple sclerosis,

pregnancy

Specialities :

Obstetrics and Gynecology

Neurology and Psychiatry

Resume

Multiple sclerosis (MS) primarily affects women of childbearing age. Data confirming a decrease in disease activity during pregnancy, as well as the effectiveness of disease-modifying therapy have contributed to the fact that more women with MS are considering the possibility of pregnancy. This leads to the fact that neurologists are more often faced with problems associated with the pregnant of patients with MS, including contraception, fertility, relapses during pregnancy and after childbirth, child safety, as well as breastfeeding. The data accumulated to date allow a doctor and a woman patient with MS to make an informed decision.

References:

Baranenko A.N., Krinichnaya I.P., Tyaglo Yu.P. i dr. (2018) Rasseyannyiy skleroz u detey. Ukr. med. chasopis, 1(2)(123): 30–33.
Alroughani R., Alowayesh M.S., Ahmed S.F. et al. (2018) Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology, 90: e840–e846. doi: 10.1212/WNL.0000000000005065.
Amato M.P., Portaccio E. (2015) Fertility, pregnancy and childbirth in patients with multiple sclerosis: Impact of disease-modifying drugs. CNS Drugs, 29: 207–220. doi: 10.1007/s40263-015-0238-y.
Bove R., Alwan S., Friedman J.M. et al. (2014) Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet. Gynecol., 124: 1157–1168. doi: 10.1097/AOG.0000000000000541.
Bove R., Rankin K., Chua A.S. et al. (2018) Oral contraceptives and MS disease activity in a contemporary real-world cohort. Mult. Scler., 24: 227–230. doi: 10.1177/1352458517692420.
Canibano B., Deleu D., Mesraoua B. et al. (2020) Pregnancy-related issues in women with multiple sclerosis: an evidence-based review with practical recommendations. J. Drug Assess., 9(1): 20–36. doi: 10.1080/21556660.2020.1721507.
Cavalla P., Rovei V., Masera S. et al. (2006) Fertility in patients with multiple sclerosis: сurrent knowledge and future perspectives. Neurol. Sci., 27: 231–239. doi: 10.1007/s10072-006-0676-x.
Compston A., Coles A. (2008) Multiple sclerosis. Lancet, 372(9648): 1502–1517. doi: 10.1016/S0140-6736(08)61620.
Confavreux C., Hutchinson M., Hours M.M. et al. (1998) Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med., 339: 285–291. doi: 10.1056/NEJM199807303390501.
De Seze J., Chapelotte M., Delalande S. et al. (2004) Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult. Scler., 10: 596–597. doi: 10.1191/1352458504ms1079sr.
D’Hooghe M.B., Nagels G., Bissay V., De Keyser J. (2010) Modifiable factors influencing relapses and disability in multiple sclerosis. Mult. Scler., 16: 773–785. doi: 10.1177/1352458510367721.
Elliott A.B., Chakravarty E.F. (2010) Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Womens Health (Lond.), 6: 431–442. doi: 10.2217/WHE.10.24.
Ferraro D., Simone A.M., Adani G. et al. (2017) Definitive childlessness in women with multiple sclerosis: a multicenter study. Neurol Sci., 38: 1453–1459. doi: 10.1007/s10072-017-2999-1.
Finer L.B., Zolna M.R. (2011) Unintended pregnancy in the United States: Incidence and disparities, 2006. Contraception, 84: 478–485. doi: 10.1016/j.contraception.2011.07.013.
Finkelsztejn A., Brooks J.B., Paschoal F.M.Jr., Fragoso Y.D. (2011) What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature. BJOG, 118: 790–797. doi: 10.1111/j.1471-0528.2011.02931.x.
Fong A., Chau C.T., Quant C. et al. (2018) Multiple sclerosis in pregnancy: Prevalence, sociodemographic features, and obstetrical outcomes. J. Matern. Fetal. Neonatal. Med., 31: 382–387. doi: 10.1080/14767058.2017.1286314.
Fragoso Y.D., Boggild M., Macias-Islas M.A. et al. (2013) The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin. Neurol. Neurosurg., 115: 154–159. doi: 10.1016/j.clineuro.2012.04.024.
Grinsted L., Heltberg A., Hagen C., Djursing H. (1989) Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis. J. Intern. Med., 226: 241–244. doi: 10.1111/j.1365–2796.1989.tb01387.x.
Hellwig K., Correale J. (2013) Artificial reproductive techniques in multiple sclerosis. Clin. Immunol., 149: 219–224. doi: 10.1016/j.clim.2013.02.001.
Hellwig K., Rockhoff M., Herbstritt S. et al. (2015) Exclusive Breastfeeding and the Effect on Postpartum Multiple Sclerosis Relapses. JAMA Neurol., 72: 1132–1138. doi: 10.1001/jamaneurol.2015.1806.
Hellwig K., Geissbuehler Y., Sabidó M. et al. (2020) Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry. J. Neurol., 267: 1715–1723. https://doi.org/10.1007/s00415-020-09762-y.
Herbstritt S., Langer-Gould A., Rockhoff M. et al. (2016) Glatiramer acetate during early pregnancy: a prospective cohort study. Mult. Scler., 22(6): 810–816. doi: 10.1177/1352458515623366.
Holmqvist P., Hammar M., Landtblom A.M. et al. (2010) Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil. Steril., 94: 2835–2837. doi: 10.1016/j.fertnstert.2010.06.045.
Hughes S.E., Spelman T., Gray O.M. et al. (2014) Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult. Scler., 20: 739–746. doi: 10.1177/1352458513507816.
Houtchens M.K., Edwards N.C., Schneider G. et al. (2018a) Pregnancy rates and outcomes in women with and without MS in the United States. Neurology, 91: e1559–e1569. doi: 10.1212/WNL.0000000000006384.
Houtchens M.K., Edwards N.C., Phillips A.L. (2018b) Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology, 91: e1570–e1578. doi: 10.1212/WNL.0000000000006382.
Kanal E., Barkovich A.J., Bell C. et al. (2013) ACR guidance document on MR safe practices: J. Magn. Reson. Imaging., 37: 501–530. doi: 10.1002/jmri.24011.
Kelly V.M., Nelson L.M., Chakravarty E.F. (2009) Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology, 73: 1831–1836. doi: 10.1212/WNL.0b013e3181c3f27d.
Langer-Gould A., Huang S.M., Gupta R. et al. (2009) Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch. Neurol., 66: 958–963. doi: 10.1001/archneurol.2009.132.
Langer-Gould A., Smith J.B., Hellwig K. et al. (2017) Breastfeeding, ovulatory years, and risk of multiple sclerosis. Neurology, 89: 563–569. doi: 10.1212/WNL.0000000000004207.
Lebrun C., Le Page E., Kantarci O. et al. (2012) Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. Mult. Scler., 18: 1297–1302. doi: 10.1177/1352458511435931.
Lu E., Zhu F., Zhao Y. et al. (2014) Birth outcomes of pregnancies fathered by men with multiple sclerosis. Mult. Scler., 20(9): 1260–1264.
MacDonald S.C., McElrath T.F., Hernandez-Diaz S. (2019) Pregnancy Outcomes in Women With Multiple Sclerosis. Am. J. Epidemiol., 188: 57–66. doi: 10.1093/aje/kwy197.
Magyari M. (2015) Role of socio-economic and reproductive factors in the risk of multiple sclerosis. Acta Neurol. Scand., 132: 20–23. doi: 10.1111/ane.12426.
Montalban X., Gold R., Thompson A.J. et al. (2018) ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult. Scler., 24(2): 96–120. doi: 10.1177/1352458517751049.
Munger K.L., Aivo J., Hongell K. et al. (2016) Vitamin D Status During Pregnancy and Risk of Multiple Sclerosis in Offspring of Women in the Finnish Maternity Cohort. JAMA Neurol., 73: 515–519. doi: 10.1001/jamaneurol. 2015.4800.
Nguyen A.L., Havrdova E.K., Horakova D. et al. (2019) Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult. Scler. Relat. Disord., 28: 235–243. doi: 10.1016/j.msard.2019.01.003.
Pakpoor J., Disanto G., Lacey M.V. et al. (2012) Breastfeeding and multiple sclerosis relapses: a meta-analysis. J. Neurol., 259: 2246–2248. doi: 10.1007/s00415-012-6553-z.
Ponsonby A.L., Lucas R.M., van der Mei I.A. et al. (2012) Offspring number, pregnancy, and risk of a first clinical demyelinating event: The AusImmune Study. Neurology, 78: 867–874. doi: 10.1212/WNL.0b013e31824c4648.
Poser S., Poser W. (1983) Multiple sclerosis and gestation. Neurology, 33: 1422–1427. doi: 10.1212/WNL.33.11.1422.
Pozzilli C., De Giglio L., Barletta V.T. et al. (2015) Oral contraceptives combined with interferon beta in multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm., 2: e120. doi: 10.1212/NXI.0000000000000120.
Rankin K., Bove R. (2018) Caring for Women with Multiple Sclerosis Across the Lifespan. Curr. Neurol. Neurosci. Rep., 18: 36. doi: 10.1007/s11910-018-0846-2.
Rejali M., Hosseini S.M., Kazemi Tabaee M.S., Etemadifar M. (2016) Assessing the Risk Factors for Multiple Sclerosis in Women of Reproductive Age Suffering the Disease in Isfahan Province. Int. J. Prev. Med., 7: 58. doi: 10.4103/2008-7802.178532.
Roux T., Courtillot C., Debs R. et al. (2015) Fecundity in women with multiple sclerosis: An observational mono-centric study. J. Neurol., 262: 957–960. doi: 10.1007/s00415-015-7663-1.
Runmarker B., Andersen O. (1995) Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain, 118: 253–261. doi: 10.1093/brain/118.1.253.
Spence R.D., Voskuhl R.R. (2012) Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front. Neuroendocrinol., 33: 105–115. doi: 10.1016/j.yfrne.2011.12.001.
Thiel S., Langer-Gould A., Rockhoff M. et al. (2016) Interferon-beta exposure during first trimester is safe in women with multiple sclerosis — A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult. Scler., 22(6): 801–809. doi: 10.1177/1352458516634872.
Thone J., Thiel S., Gold R., Hellwig K. (2017) Treatment of multiple sclerosis during pregnancy — safety considerations. Expert Opin. Drug Saf., 16: 523–534. doi: 10.1080/14740338.2017.1311321.
Vaughn C., Bushra A., Kolb C., Weinstock-Guttman B. (2018) An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis. CNS Drugs., 32: 161–178. doi: 10.1007/s40263-018-0496-6.
Voskuhl R.R., Wang H., Wu T.C. et al. (2016) Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol., 15: 35–46. doi: 10.1016/S1474-4422(15)00322-1.
Vukusic S., Hutchinson M., Hours M. et al. (2004) Pregnancy and multiple sclerosis (the PRIMS study): Clinical predictors of post-partum relapse. Brain, 127: 1353–1360. doi: 10.1093/brain/awh152.
Wallin M.T., Culpepper W.J., Campbell J.D. et al. (2019) The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology, 92: e1029–e1040. doi: 10.1212/WNL.0000000000007035.
Xiao W.L., Liu X.Y., Liu Y.S. et al. (2017) The relationship between maternal corticosteroid use and orofacial clefts-a meta-analysis. Reprod. Toxicol., 69: 99–105. doi: 10.1016/j.reprotox.2017.02.006.